Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Abstract Background In recent years, programmed cell death protein-1 inhibitors, including sintilimab, have significantly prolonged the overall survival time of patients with unresectable or metastatic hepatocellular carcinoma (HCC); however, the cost-effectiveness of sintilimab is unclear. The aim...

Full description

Bibliographic Details
Main Authors: Ting Zhou, Xintian Wang, Yingdan Cao, Lan Yang, Zijing Wang, Aixia Ma, Hongchao Li
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Health Services Research
Subjects:
Hepatocellular carcinoma
Sintilimab
Lenvatinib
Cost-effectiveness
PD-1
Online Access:https://doi.org/10.1186/s12913-022-08661-4

Internet

https://doi.org/10.1186/s12913-022-08661-4

Similar Items